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OBJECTIVE
Individuals with type 1 diabetes have experienced an increase in life expectancy,
yet it is unknown what level of glycemic control is ideal for maintaining late-life
brain health. We investigated the association of long-term glycemic control with
dementia in older individuals with type 1 diabetes.
RESEARCH DESIGN AND METHODS
We followed 3,433 members of a health care system with type 1 diabetes, aged ‡50
years, from 1996 to 2015. Repeated measurements of hemoglobin A1c (HbA1c),
dementia diagnoses, and comorbidities were ascertained from health records. Cox
proportional hazards models were fit to evaluate the association of time-varying
glycemic exposure with dementia, with adjustment for age, sex, race/ethnicity,
baseline health conditions, and frequency of HbA1c measurement.
RESULTS
Over a mean follow-up of 6.3 years, 155 individuals (4.5%) were diagnosed with
dementia. Patients with ‡50% of HbA1c measurements at 8–8.9% (64–74 mmol/
mol) and ‡9% (‡75 mmol/mol) had 65% and 79% higher risk of dementia,
respectively, compared with those with <50% of measurements exposed (HbA1c
8–8.9% adjusted hazard ratio [aHR] 1.65 [95% CI 1.06, 2.57] and HbA1c ‡9% aHR 1.79
[95% CI 1.11, 2.90]). By contrast, patients with ‡50% of HbA1c measurements at
6–6.9% (42–52 mmol/mol) and 7–7.9% (53–63 mmol/mol) had a 45% lower risk
of dementia (HbA1c 6–6.9% aHR 0.55 [95% CI 0.34, 0.88] and HbA1c 7–7.9% aHR
0.55 [95% CI 0.37, 0.82]).
CONCLUSIONS
Among older patients with type 1 diabetes, those with majority exposure to HbA1c
8–8.9% and ‡9% had increased dementia risk, while those with majority exposure
to HbA1c 6–6.9% and 7–7.9% had reduced risk. Currently recommended glycemic
targets for older patients with type 1 diabetes are consistent with healthy brain
aging.
Type 1 diabetes is associated with a number of micro- and macrovascular compli-
cations, among them retinopathy, neuropathy, nephropathy, stroke, and coronary
artery disease (1,2). The Diabetes Control and Complications Trial (DCCT), a landmark
clinical trial, demonstrated that intensive diabetes therapy, aimed at achieving
glycemic control as close to the nondiabetes range as safely possible, decreases the
risk for developing these complications (3–6). Studies have also found glycemic con-
trol to be an important predictor of cognition among people with type 1 and type 2
diabetes (7–11) and a predictor of dementia in individuals with type 2 diabetes as well
as in people without diabetes (11–13). In recent decades, survival among individuals
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with type 1 diabetes has improved sig-
nificantly (14). This increase in life ex-
pectancy is accompanied by an increased
risk of developing aging-related diseases,
such as dementia. Indeed, prior work
has established type 1 diabetes as a risk
factor for dementia (15). However, the
relationship between glycemic control
and subsequent risk of dementia in those
with type 1 diabetes remains unclear.
Hemoglobin A1c (HbA1c) is an estab-
lished measure that integrates glucose
control over the prior 2–3 months and is
widely used to guide clinical manage-
ment of type 1 diabetes (16,17). Cumu-
lative glycemic exposure, as measured by
multiple HbA1c measures over time, has
previously been used to evaluate glyce-
mic trajectories and their association
with a number of diabetes complications
(18,19). Electronic health records cap-
ture HbA1c values collected over time
allowing for a more thorough long-term
characterization of glycemic exposure
than is reflected by a single HbA1c mea-
sure. In this study, we leverage data
collected over a span of 19 years to
examine the association of cumulative
glycemic exposure, as measured by re-
peated HbA1c values, with incident de-
mentia among older adults with type 1
diabetes. We also examine the potential
for a threshold of glycemic exposure
above or below which risk of dementia
increases.
RESEARCH DESIGN AND METHODS
Study Population
Kaiser Permanente Northern California
(KPNC) is a large, integrated health care
delivery system that provides com-
prehensive medical care to .4 million
members representing ;30% of the
surrounding geographic region. KPNC
members are representative of the gen-
eral population with respect to race/
ethnicity and socioeconomic status
except at the extreme tails of income
distribution (20,21). KPNC maintains a
Diabetes Registry that identifies all
members with diabetes using a combi-
nation of pharmacy and laboratory in-
formation, hospitalization records, and
outpatient diagnoses. Within the Diabe-
tes Registry, we restricted the sample to
individuals aged 50 years or older during
the study period (1 January 1996 to
30 September 2015) and identified in-
dividuals with type 1 diabetes using the
following three criteria, all of which had
to bemet: 1) at least two type 1 diabetes
ICD-9 diagnoses without a type 2 diabe-
tes code or $75% of the individual’s
diabetes-related diagnostic codes indi-
cating type 1 diabetes, 2) at least one
insulin prescription indicative of type 1
diabetes filled during the study period,
and 3) no filled prescriptions for any
hypoglycemic agents other than insulin
(22). We further excluded individuals
with prevalent dementia at baseline
(n = 42) and individuals with no HbA1c
measurements during the study period
(n = 309). Cohort entry was the first date
between 1 January 1996 and 30 Septem-
ber 2015 that the patient was $50 years
old and had type 1 diabetes based on the
criteria described above. Once a person
entered the cohort they were followed
until one of the following occurred: di-
agnosis of dementia, KPNC membership
lapse of $90 days, death, or the end of
the study (30 September 2015).
Outcome
Dementia diagnoses were identified
based on electronic medical records of
inpatient and outpatient encounters
from 1 January 1996 to 30 September
2015 based on the following ICD-9
codes: Alzheimer disease (331.0), non-
specific dementia (290.0x, 290.1x, 290.2x,
290.3x, 294.1x, 294.2x, and 294.8), and
vascular dementia (290.4x). A similar
algorithm for the diagnosis of dementia
has been used in previous studies on this
population (23,24).
Exposure
Clinical measurements of HbA1c measure-
ments were obtained from the KPNC
laboratory database from the time of
cohort entry to the end of follow-up. For
each patient, we extracted every HbA1c
laboratory value that was measured dur-
ing the time the patient was in follow-up.
Beginning with their first available HbA1c
measure, each patient was categorized
based on the percent of their HbA1c mea-
surements that fell into the following
categories: HbA1c,6% (,42mmol/mol),
6–6.9% (42–52 mmol/mol), 7–7.9%
(53–63 mmol/mol), 8–8.9% (64–74
mmol/mol), and $9% ($75 mmol/
mol). Each time a new value was cap-
tured, we recalculated their cumulative
glycemic exposure. We operationalized
the exposure two ways: 1) percent of
HbA1c measurements (,10% [referent
group], 10 to,25%,25 to,75%,or$75%)
that fell within the above-mentioned
HbA1c categories and 2) as a binary in-
dicator of whether$50% of an individ-
ual’s HbA1c measures fell within the
aforementioned HbA1c categories.
Covariates
Demographic characteristics such as age,
sex, race, and ethnicity were obtained
through KPNC membership databases
and were recorded at cohort entry.
We collected diagnoses of the following
health conditions at baseline: peripheral
artery disease, nephropathy, retinopa-
thy, neuropathy, stroke, myocardial in-
farction, and severe hypoglycemic and
hyperglycemic events resulting in emer-
gency room visit or hospitalization (ICD-9
codes used to define these covariates are
available in Supplementary Table 1). We
also calculated the frequency of HbA1c
measurement for each patient; this was
operationalized as a time-varying covar-
iate that was updated each time a new
HbA1c measurement was captured for a
given individual to reflect the total num-
ber of HbA1c measurements collected
for that individual divided by their total
follow-up time.
Statistical Analysis
We examined the distribution of pa-
tient demographics and comorbidities at
baseline in the overall sample and by
dementia status using x2 and t tests. We
specified Cox proportional hazards mod-
els to estimate the association between
categories of cumulative exposure to
HbA1c and risk of dementia. Because
dementia risk is highly correlated with
aging, age was used as the time scale (as
opposed to time in the study) beginning
with age at cohort entry up to age at
the end of follow-up.
We used a multistep approach to ex-
amine robustness of findings to model
specification. Four models were exam-
ined: 1) an unadjusted model using
dementia as the outcome, HbA1c thresh-
olds as the exposure, and age as the time
scale; 2) a model adjusted for sex and
race/ethnicity; 3) a model additionally
adjusted for baseline health conditions,
including peripheral artery disease,
nephropathy, neuropathy, retinopathy,
stroke, myocardial infarction, and prior
severe hypo- and hyperglycemic hospi-
talization events; and 4) a model addi-
tionally adjusted for frequency of HbA1c
measurement. Sensitivity analyses were
2340 HbA1c and Dementia in Type 1 Diabetes Diabetes Care Volume 41, November 2018
conducted among the subset of patients
who were $65 years of age at baseline.
We used SAS, version 9.3, for all analyses.
RESULTS
The final analytic cohort consisted of
3,433 individuals (mean age at cohort
entry 5 56.1 years old; 47.1% female)
(Table 1). On average, individuals who
developed dementia during follow-up
were older at cohort entry (64.4 vs.
55.7 years) and were more likely to
have a history of stroke (7.7% compared
with 3.5%) at baseline. The mean follow-
up time was 6.3 years (median 4.8 years
[interquartile range (IQR) 1.7, 9.9]), and
the mean number of HbA1c measure-
ments was 13.5 (median 9.0 [IQR 3.0,
20.00]). By the end of follow-up on 30
September 2015, 155 members (4.5%)
were diagnosed with dementia, 860
(25.1%) had a lapse of at least 90 days
in membership coverage, 519 (15.1%)
died without a dementia diagnosis, and
1,899 (55.3%) were still alive without
dementia diagnosis. Among the 155
members who developed dementia over
follow-up, the mean age at dementia di-
agnosis was 64.6 years (median 63.6
years [IQR 56.1, 72.3]).
In Cox proportional hazards models,
dementia risk was higher in those with
increased exposure to HbA1c 8–8.9% (64–
74 mmol/mol) and $9% ($75 mmol/mol)
and lower in those with HbA1c 6–6.9%
(42–52 mmol/mol) and 7–7.9% (53–
63 mmol/mol). In fully adjusted models,
compared with those with minimal ex-
posure (,10% of HbA1c measurements)
to HbA1c 8–8.9% and $9%, those with
prolonged exposure ($75% of measure-
ments) were 2.51 and 2.13 times more
likely to develop dementia, respectively
(HbA1c 8–8.9% fully adjusted hazard ratio
[aHR] 2.51 [95% CI 1.23, 5.11] and
HbA1c $9% aHR 2.13 [95% CI 1.13,
4.01]) (Table 2). In contrast, prolonged
exposure to HbA1c 6–6.9 and 7–7.9%
was associated with a 58% lower and
61% lower risk of dementia, respectively
(HbA1c 6–6.9% aHR 0.42 [95% CI 0.21,
0.83] and HbA1c 7–7.9% aHR 0.39 [95%CI
0.18, 0.83]).
Results were similar in Cox models ex-
amining cumulative glycemic exposure
based on whether a majority (.50%) of
an individual’s available HbA1c measure-
ments fell into the following categories
of HbA1c:,6, 6–6.9, 7–7.9, 8–8.9, and$9%
(Table 3). Majority exposure to HbA1c
Table 1—Sample characteristics of final analytic cohort at baseline by dementia status
No dementia Dementia Overall P
n (%) 3,278 (95.48) 155 (4.52) 3,433
Demographics
Age at entry (years)
Mean (SD) 55.7 (7.7) 64.0 (9.9) 56.1 (8.0) ,0.0001
Median (IQR) 51.7 (50.3, 58.9) 63.3 (55.9, 71.8) 51.9 (50.3, 59.7)
Range (min, max) (50.0, 95.6) (50.0, 87.6) (50.0, 95.6)
Race
White 2,628 (80.2) 123 (79.4) 2,751 (80.1) 0.80
Asian 128 (3.9) 4 (2.6) 132 (3.8) 0.40
Black 149 (4.5) 8 (5.2) 157 (4.6) 0.72
Hispanic 171 (5.2) 8 (5.2) 179 (5.2) 0.98
Other 117 (3.6) 12 (7.7) 129 (3.7) 0.01
Missing 85 (2.6) 0 (0.0) 85 (2.5) 0.04
Female 1,547 (47.2) 71 (45.8) 1,618 (47.1) 0.74
Baseline health characteristics
Peripheral arterial disease 223 (6.8) 12 (7.7) 235 (6.8) 0.65
Neuropathy 469 (14.3) 19 (12.3) 488 (14.2) 0.48
Nephropathy 558 (17.0) 22 (14.2) 580 (16.9) 0.36
Severe diabetic retinopathy 1,037 (31.6) 54 (34.8) 1,091 (31.8) 0.40
Stroke 114 (3.5) 12 (7.7) 126 (3.7) 0.01
Myocardial infarction 82 (2.5) 3 (1.9) 85 (2.5) 0.66
Hyperglycemic event 285 (8.7) 9 (5.8) 294 (8.6) 0.21
Hypoglycemic event 486 (14.8) 17 (11.0) 503 (14.7) 0.18
Study characteristics
Baseline HbA1c category (%)
,6 155 (4.7) 4 (2.6) 159 (4.6) 0.21
6–6.9 635 (19.4) 30 (19.4) 665 (19.4) 0.99
7–7.9 926 (28.2) 39 (25.2) 965 (28.1) 0.40
8–8.9 654 (20.0) 42 (27.1) 696 (20.3) 0.03
$9 908 (27.7) 40 (25.8) 948 (27.6) 0.61
Years of follow-up
Mean (SD) 6.2 (5.2) 6.8 (4.9) 6.3 (5.2) 0.20
Median (IQR) 4.7 (1.7, 9.8) 5.9 (2.4, 10.6) 4.8 (1.7, 9.9)
Range (min, max) (0.0, 19.7) (0.0, 17.8) (0.0, 19.7)
Number of HbA1c measurements
Mean (SD) 13.4 (12.6) 15.4 (13.4) 13.5 (12.6) 0.05
Median (IQR) 9.0 (3.0, 20.0) 11.0 (5.0, 25.0) 9.0 (3.0, 20.0)
Range (min, max) (1.0, 105.0) (1.0, 60.0) (1.0, 105.0)
Data are presented as n (%) unless otherwise indicated. P values were calculated using the x2 test or Student t test. max, maximum; min, minimum.
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8–8.9 and $9% was associated with an
increased risk of dementia (HbA1c 8–
8.9% aHR 1.65 [95% CI 1.06, 2.57] and
HbA1c $9% aHR 1.79 [95% CI 1.11, 2.90]),
while majority exposure to HbA1c 6–
6.9 and 7–7.9% was associated with a
reduced risk of dementia (HbA1c 6–
6.9% aHR 0.55 [95% CI 0.34, 0.88] and
HbA1c 7–7.9% aHR 0.55 [95% CI 0.37,
0.82]). Majority exposure to HbA1c ,6%
(,42 mmol/mol) was associated with in-
creased dementia risk in age-adjusted
models (HR 2.06 [95% CI 1.11, 3.82]),
though findings did not remain significant
in fully adjustedmodels (aHR 1.45 [95%
CI 0.71, 2.92]). Findings were similar in
sensitivity analyses among the subset of
members who were $65 years of age at
baseline (n = 1,082 [32% of the sample]),
though the increased risk associated
with majority time at HbA1c$9% was no
longer statistically significant (Supple-
mentary Table 2).
CONCLUSIONS
In this large sample of older adults with
type 1 diabetes, we found that cumula-
tive exposure to higher levels of HbA1c
(8–8.9 and $9%) was associated with
an increased risk of dementia, while
Table 2—Cumulative glycemic exposure and risk of dementia among older adults with type 1 diabetes
Age-adjusted HR
(95% CI)
HR (95% CI) adjusted
for race and sex
HR (95% CI) adjusted
for race, sex, and baseline
health conditions*
HR (95% CI) adjusted for race, sex,
baseline health conditions,* and
frequency of HbA1c measurement
% of HbA1c
measurements ,6%
,10 ref ref ref ref
10 to ,25 1.63 (0.88, 3.04) 1.55 (0.83, 2.89) 1.50 (0.80, 2.82) 1.51 (0.80, 2.83)
25 to ,75 1.54 (0.85, 2.78) 1.46 (0.80, 2.65) 1.41 (0.77, 2.57) 1.41 (0.77, 2.57)
$75 1.64 (0.72, 3.72) 1.59 (0.70, 3.63) 1.02 (0.43, 2.42) 1.03 (0.43, 2.44)
% of HbA1c measurements
6.0–6.9%
,10 ref ref ref ref
10 to ,25 0.83 (0.51, 1.34) 0.82 (0.50, 1.32) 0.85 (0.53, 1.38) 0.86 (0.53, 1.39)
25 to ,75 0.66 (0.45, 0.96) 0.65 (0.44, 0.95) 0.66 (0.45, 0.98) 0.66 (0.45, 0.98)
$75 0.41 (0.21, 0.81) 0.39 (0.20, 0.79) 0.42 (0.21, 0.83) 0.42 (0.21, 0.83)
% of HbA1c measurements
7.0–7.9%
,10 ref ref ref ref
10 to ,25 1.15 (0.73, 1.81) 1.15 (0.73, 1.81) 1.22 (0.77, 1.93) 1.22 (0.77, 1.94)
25 to ,75 0.63 (0.44, 0.92) 0.65 (0.45, 0.95) 0.69 (0.48, 1.01) 0.69 (0.48, 1.01)
$75 0.36 (0.17, 0.77) 0.39 (0.18, 0.81) 0.39 (0.19, 0.83) 0.39 (0.18, 0.83)
% of HbA1c measurements
8.0–8.9%
,10 ref ref ref ref
10 to ,25 1.67 (1.09, 2.57) 1.67 (1.09, 2.58) 1.77 (1.15, 2.73) 1.78 (1.15, 2.74)
25 to ,75 1.50 (1.04, 2.18) 1.49 (1.02, 2.16) 1.54 (1.06, 2.25) 1.55 (1.06, 2.26)
$75 2.37 (1.16, 4.82) 2.32 (1.14, 4.72) 2.48 (1.22, 5.07) 2.51 (1.23, 5.11)
% of HbA1c
measurements $9%
,10 ref ref ref ref
10 to ,25 2.19 (1.40, 3.42) 2.15 (1.37, 3.38) 2.25 (1.43, 3.54) 2.26 (1.44, 3.55)
25 to ,75 1.78 (1.16, 2.72) 1.76 (1.15, 2.71) 1.83 (1.19, 2.83) 1.83 (1.19, 2.83)
$75 2.15 (1.17, 3.98) 2.17 (1.17, 4.04) 2.15 (1.14, 4.04) 2.13 (1.13, 4.01)
Estimates obtained from Cox proportional hazards models with age as time scale. ref, reference. *Each of the following baseline health conditions
was adjusted for in the model: history of stroke, myocardial infarction, nephropathy, neuropathy, severe diabetic retinopathy, peripheral arterial
disease, hyperglycemic events, and hypoglycemic events.





HR (95% CI) adjusted
for race and sex
HR (95% CI) adjusted
for race, sex, and baseline
health conditions*
HR (95% CI) adjusted for race, sex,
baseline health conditions,* and
frequency of HbA1c measurement
,6% 2.06 (1.11, 3.82) 2.03 (1.10, 3.78) 1.44 (0.75, 2.77) 1.45 (0.71, 2.92)
6–6.9% 0.55 (0.34, 0.88) 0.53 (0.33, 0.85) 0.54 (0.34, 0.87) 0.55 (0.34, 0.88)
7–7.9% 0.52 (0.35, 0.77) 0.55 (0.37, 0.82) 0.55 (0.37, 0.82) 0.55 (0.37, 0.82)
8–8.9% 1.57 (1.01 2.46) 1.58 (1.01, 2.47) 1.64 (1.05, 2.57) 1.65 (1.06, 2.57)
$9% 1.82 (1.14, 2.90) 1.80 (1.12, 2.89) 1.80 (1.11, 2.90) 1.79 (1.11, 2.90)
Estimates obtained from Cox proportional hazardsmodels with age as time scale. *Each of the following baseline health conditionswas adjusted for in
the model: history of stroke, myocardial infarction, nephropathy, neuropathy, severe diabetic retinopathy, peripheral arterial disease, hyperglycemic
events, and hypoglycemic events.
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cumulative exposure to well-controlled
HbA1c (6–6.9 and7–7.9%)was associated
with adecreased risk of dementia. In fully
adjusted models, compared with those
with minimal exposure to HbA1c 8–8.9%
and HbA1c $9%, those with prolonged
exposure were more than twice as likely
to develop dementia over the course of
follow-up (Table 2). By contrast, dementia
risk was ;60% lower among those with
prolonged exposure to well-controlled
HbA1c (6–6.9 and 7–7.9%) compared
with those with minimal time at well-
controlled levels of HbA1c.
To our knowledge, this is the first study
to investigate the association between
long-term glycemic control and the risk of
dementia in older individuals with type
1 diabetes. Our results complement and
extend previous studies that have re-
ported an association between chronic
hyperglycemia and decreased cognitive
function in children and adolescents with
type 1 diabetes (25,26), as well as studies
reporting an association between poor
glycemic control and decreased cogni-
tive functioning in middle-aged adults
with type 1 diabetes and older adults with
type 2 diabetes (7–11). Our findings are
also consistent with previous studies
that found an increased dementia risk
associated with poorer glycemic con-
trol among adults with type 2 diabetes
and adults without diabetes (11–13).
Whether these findings applied to de-
mentia risk among older adults with
type 1 diabetes was previously unknown.
Another interesting finding from our
study was the suggestion that cumula-
tive exposure to HbA1c ,6% was asso-
ciated with a nonsignificant increased
risk of dementia. However, the number
of individuals with majority exposure to
HbA1c,6% was very small, and, as such,
we are underpowered to further inves-
tigate this association in the current
study. Therefore, this should be treated as
a preliminary and hypothesis-generating
finding that should be examined in greater
detail in future studies with larger sam-
ple sizes and the appropriate power to
explore these potential associations.
In our study of 3,433 older adults with
type 1 diabetes, 155 (4.5%) individuals
developed dementia over an average of
6.3 years of follow-up. Among thosewho
developed dementia, the average age
at dementia diagnosis was 64.6 years.
A large-scale study using administrative
health data from1998 to 2011 in England
reported a similar incidence of dementia
among a subset of adults aged$50 years
with type 1 diabetes (3.99% developed
dementia), though the average length of
follow-up was not reported for this spe-
cific age-group (15). Prior studies have
also found type 1 diabetes to be a risk
factor for dementia (15) and have re-
ported the average age at onset of de-
mentia to be 2–5 years earlier in those
with diabetes compared with those
without diabetes (27,28). Taken together,
these results provide further evidence
that older adults with type 1 diabetes are
at increased risk of developing dementia
and may have increased risk at younger
ages than the general population. Our
results, however, suggest that effective
glycemic control could be an important
tool for reducing risk of dementia among
older adults with type 1 diabetes.
Accumulating evidence suggests an
increasing trend in the incidence of type
1 diabetes (29–31). Additionally, as a
result of treatment advances in recent
decades, individuals with type 1 diabe-
tes are living longer, resulting in an in-
creased proportion of the population
with type 1 diabetes living into old
age (32–34). While extensive research
has been done to determine appropriate
glycemic targets for vascular complica-
tions in type 1 diabetes (3–6), little is
known about the role of glycemic control
on dementia. Given the aging population
of individuals with type 1 diabetes and
the importance of cognitive function in
type 1 diabetes self-care, understanding
the role of glycemic control on dementia
risk is of great importance.
Pathophysiological mechanisms by
which glycemic control may affect de-
mentia risk are still poorly understood
but are hypothesized to result from
structural brain abnormalities stemming
from chronic exposure to hyperglycemia
and/or recurrent severe hypoglycemia.
Studies in adults and youth with type 1
diabetes have reported an association
between chronic hyperglycemia (defined
using lifetime HbA1c history and using
retinopathy as an indicator of chronic
exposure) and gray matter density loss
(35–37). Studies examining the asso-
ciation between severe hypoglycemic
events and changes in brain structure
have been less consistent, with some
reporting increased gray matter density
loss and a higher prevalence of cortical
atrophy in thosewith a history of frequent
exposure to severe hypoglycemia (36,38),
while another study reported no associ-
ation (37). In the ACCORD MIND (Action
to Control Cardiovascular Risk in Diabe-
tes Memory in Diabetes) trial, compared
with standard glycemic control, intensive
glycemic control was associated with
greater total brain volume, suggesting
that intensive glycemic control may re-
duce brain atrophy related to diabetes
(39). The goal of this study was to de-
termine whether an association exists
between patterns of HbA1c control and
risk of dementia in this population of
adults with type 1 diabetes; this was
previously unknown. Understanding why
glycemic patterns are associated with
dementia is a much-needed area for
future study, particularly with regard of
the potential role of intercurrent micro-
and macrovascular complications.
The current study has several strengths.
To our knowledge, it is the first study to
investigate the association between
long-term glycemic control and demen-
tia in a large population of older adults
with type 1 diabetes. The availability of
multiple longitudinal HbA1c measure-
ments (mean 13.5 [SD 12.6]) allows
for a more accurate characterization of
long-term glycemic control, and the lon-
gitudinal design allows for observation
of incident dementia. Finally, KPNC main-
tains high-quality electronic health re-
cord data with a low turnover rate and
uniform access to quality medical care
allowing for inclusion of a range of di-
abetes-specific comorbidities and obser-
vation of incident dementia.
There were several limitations to our
study as well. One of the biggest limi-
tations was the reliance on clinical data
for our analyses. Because clinical data
are collected for reasons other than re-
search, our data may be subject to hidden
confounding and bias; for this reason, we
suggest that our findings be interpreted
as hypothesis generating as opposed to
conclusive evidence. Another limitation
was the lack of information regarding
age of diabetes onset. Age of onset may
significantly affect glycemic control in
later life as well as risk of dementia.
Additionally, we did not have data on
cognitive performance measures. As
such, in this study, we were unable to
assess the association between long-
term glycemic control and changes
in cognition. We were also unable to
investigate the possible reverse effects
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of cognitive decline on glycemic control.
A clinical diagnosis of dementia is likely
preceded by a period of cognitive decline
during which one’s ability to properly
manage glycemia may be impacted; this
is an especially important limitation in
this population of older adults with type
1 diabetes where self-care plays such an
important role in disease management.
The use ofmedical diagnoses rather than
routine cognitive testing to assess de-
mentia status is another possible limita-
tion in this study that may have resulted
in underascertainment of the true num-
ber of incident cases. Additionally, based
on the available data, we were unable to
distinguish between different types of
dementia as we did not have brain im-
aging, and we were not able to examine
the potential mediating role of vascular
and renal complications on the associ-
ation between dementia and glycemic
patterns. This study was performed
in a unique cohort of individuals with
type 1 diabetes who have survived to
older ages, which may induce selective
survivorship bias, a bias in which the
study population is comprised of healthy
survivors who outlived their peers; if
present, this bias would likely underes-
timate the true association of long-term
glycemic control on dementia risk. An-
other important limitation was the sourc-
ing of our cohort from a single large health
care system in northern California, which
may limit generalizability of our findings.
Finally, HbA1c is an integratedmeasureof
glucose levels over time. While HbA1c is
the best assessment available to evalu-
ate long-term glycemic trajectories, it does
not reflect day-to-day glycemic variabil-
ity or glycemic excursions.
In conclusion, among older patients
with type 1 diabetes, increased expo-
sure to HbA1c 8–8.9% (64–74mmol/mol)
and $9% ($75 mmol/mol) was asso-
ciated with an increased risk of de-
mentia, while maintaining HbA1c 6–6.9%
(42–52 mmol/mol) and 7–7.9% (53–63
mmol/mol) was associated with a signif-
icant reduction in dementia risk. Our
study complements previous literature
by extending the association between
HbA1c and dementia to a previously
unstudied population in an older co-
hort with type 1 diabetes. We are also
able to suggest HbA1c thresholds and
the risk associated with percentage of
time spent beyond these thresholds.
It is gratifying to see that the current
recommendations for glycemic control
in older adults with diabetes are largely
consistent with the levels needed to pro-
tect the brain (40,41). The increasing in-
cidence of type 1 diabetes coupled with
advances in treatment of type 1 diabe-
tes has resulted in an unprecedented
number of older adults living with and
managing type 1 diabetes. Our findings
suggest glycemic control as an impor-
tant and potentially modifiable factor
that can be targeted to reduce demen-
tia risk among older adults with type 1
diabetes.
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